RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제
      • 좁혀본 항목 보기순서

        • 원문유무
        • 원문제공처
        • 등재정보
        • 학술지명
        • 주제분류
        • 발행연도
        • 작성언어
        • 저자
          펼치기

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • Clinical Efficacy and Possible Applications of Genomics in Lung Cancer

        Alharbi, Khalid Khalaf Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.5

        The heterogeneous nature of lung cancer has become increasingly apparent since introduction of molecular classification. In general, advanced lung cancer is an aggressive malignancy with a poor prognosis. Activating alterations in several potential driver oncogenic genes have been identified, including EGFR, ROS1 and ALK and understanding of their molecular mechanisms underlying development, progression, and survival of lung cancer has led to the design of personalized treatments that have produced superior clinical outcomes in tumours harbouring these mutations. In light of the tsunami of new biomarkers and targeted agents, next generation sequencing testing strategies will be more appropriate in identifying the patients for each therapy and enabling personalized patients care. The challenge now is how best to interpret the results of these genomic tests, in the context of other clinical data, to optimize treatment choices. In genomic era of cancer treatment, the traditional one-size-fits-all paradigm is being replaced with more effective, personalized oncologic care. This review provides an overview of lung cancer genomics and personalized treatment.

      • KCI등재

        Enabling Fine-grained Access Control with Efficient Attribute Revocation and Policy Updating in Smart Grid

        ( Hongwei Li ),( Dongxiao Liu ),( Khalid Alharbi ),( Shenmin Zhang ),( Xiaodong Lin ) 한국인터넷정보학회 2015 KSII Transactions on Internet and Information Syst Vol.9 No.4

        In smart grid, electricity consumption data may be handed over to a third party for various purposes. While government regulations and industry compliance prevent utility companies from improper or illegal sharing of their customers` electricity consumption data, there are some scenarios where it can be very useful. For example, it allows the consumers` data to be shared among various energy resources so the energy resources are able to analyze the data and adjust their operation to the actual power demand. However, it is crucial to protect sensitive electricity consumption data during the sharing process. In this paper, we propose a fine-grained access control scheme (FAC) with efficient attribute revocation and policy updating in smart grid. Specifically, by introducing the concept of Third-party Auditor (TPA), the proposed FAC achieves efficient attribute revocation. Also, we design an efficient policy updating algorithm by outsourcing the computational task to a cloud server. Moreover, we give security analysis and conduct experiments to demonstrate that the FAC is both secure and efficient compared with existing ABE-based approaches.

      • KCI등재후보

        Feasibility and safety of day-surgery laparoscopic cholecystectomy

        Saud Al-Omani,Helayel Almodhaiberi,Bander Ali,Abdulrahman Alballa,Khalid Alsowaina,Ibrahim Alhasan,Abdullah Algarni,Haifa Alharbi,Degna,Maria-Rosene Alarma 한국간담췌외과학회 2015 한국간담췌외과학회지 Vol.19 No.3

        Backgrounds/Aims: We report our experience with day-surgery laparoscopic cholecystectomy and assess its feasibility and safety. Methods: Data was collected on all the patients who underwent day-surgery laparoscopic cholecystectomy between February 2009 and February 2014 at Prince Sultan Military Medical City, Riyadh, Kingdom of Saudi Arabia. All patients had symptomatic cholelithiasis that was proven on imaging studies with clearance of the common bile duct. The patient biographical data (age, gender, American Society of Anaesthesiology status, medical comorbidities) and surgical outcomes were then obtained. There was an evaluation of the success rate of day-surgery laparoscopic cholecystectomy, reasons for unexpected admission, and the re-admission rate. Results: A total of 1,140 patients were included in this study. The success rate for day-surgery laparoscopic cholecystectomy was 96%. The reasons for unexpected hospital admission for 46 patients (4%) included persistent abdominal pain and postoperative emesis. The postoperative re-admission rate was 0.4% (5 patients). There were no major complications, and the conversion rate was 0.5% (6 patients). Conclusions: We suggest that day-surgery laparoscopic cholecystectomy is both safe and feasible in a local setting. Careful patient selection is essential in ensuring a high success rate.

      • Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study

        Kavitha, Matam,Iravathy, Goud,Adi Maha, Lakshmi M,Ravi, V,Sridhar, K,Vijayanand, Reddy P,Chakravarthy, Srinivas,Prasad, SVSS,Tabassum, Shaik Nazia,Shaik, Noor Ahmad,Syed, Rabbani,Alharbi, Khalid Khala Asian Pacific Journal of Cancer Prevention 2015 Asian Pacific journal of cancer prevention Vol.16 No.16

        Epidermal growth factor receptor (EGFR) is one of the targeted molecular markers in many cancers including lung malignancies. Gefitinib and erlotinib are two available therapeutics that act as specific inhibitors of tyrosine kinase (TK) domains. We performed a case-control study with formalin-fixed paraffin-embedded tissue blocks (FFPE) from tissue biopsies of 167 non-small cell lung carcinoma (NSCLC) patients and 167 healthy controls. The tissue biopsies were studied for mutations in exons 18-21 of the EGFR gene. This study was performed using PCR followed by DNA sequencing. We identified 63 mutations in 33 men and 30 women. Mutations were detected in exon 19 (delE746-A750, delE746-T751, delL747-E749, delL747-P753, delL747-T751) in 32 patients, exon 20 (S786I, T790M) in 16, and exon 21 (L858R) in 15. No mutations were observed in exon 18. The 63 patients with EFGR mutations were considered for upfront therapy with oral tyrosine kinase inhibitor (TKI) drugs and have responded well to therapy over the last 15 months. The control patients had no mutations in any of the exons studied. The advent of EGFR TKI therapy has provided a powerful new treatment modality for patients diagnosed with NSCLC. The study emphasizes the frequency of EGFR mutations in NSCLC patients and its role as an important predictive marker for response to oral TKI in the south Indian population.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼